Issues in the pharmacological treatment of anxiety disorders

REFERENCES

• Shapira N A, Ward H E, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive–compulsive disorder. Biological Psychiatry 2004; 55: 553–555
   PubMed Web of Science ®Google Scholar
• Bystritsky A, Ackerman D L, Rosen R M, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive–compulsive disorder using adjunctive olanzapine: a placebocontrolled trial. Journal of Clinical Psychiatry 2004; 65: 565–568
   PubMed Web of Science ®Google Scholar
• McDougle C J, Epperson C N, Pelton G H, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive–compulsive disorder. Archives of General Psychiatry 2000; 57: 794–801
   PubMed Web of Science ®Google Scholar
• Hollander E, Rossi N B, Sood E, et al. Risperidone augmentation in SRI-resistant obsessive compulsive disorder: a preliminary double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology 2003; 6: 397–401
   PubMed Web of Science ®Google Scholar
• Woods S W, Nagy L M, Kolesar A S, et al. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. Journal of Clinical Psychopharmacology 1992; 12: 32–38
   PubMed Web of Science ®Google Scholar
• Goddard A W, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. Archives of General Psychiatry 2001; 58: 681–686
   PubMed Web of Science ®Google Scholar
• Pollack M H, Simon N M, Worthington J J, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. Journal of Psychopharmacology 2003; 17: 276–282
   PubMed Web of Science ®Google Scholar
• Seedat S, Stein M B. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Journal of Clinical Psychiatry 2004; 65: 244–248
   PubMed Web of Science ®Google Scholar
• Carli V, Sarchiapone M, Camardese G, et al. Mirtazapine in the treatment of panic disorder. Archives of General Psychiatry 2002; 59: 661–662
   PubMed Web of Science ®Google Scholar
• Feltner D E, Crockatt J G, Dubovsky S J, et al. A randomized, double-blind, placebocontrolled, fixed-dose, multicenter study of pregabalin in patientswith generalized anxiety disorder. Journal of Clinical Psychopharmacology 2003; 23: 240–249
   PubMed Web of Science ®Google Scholar
• Pande A C, Crockatt J G, Feltner D E, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. American Journal of Psychiatry 2003; 160: 533–540
   PubMed Web of Science ®Google Scholar
• Pande A C, Feltner D E, Jefferson J W, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. Journal of Clinical Psychopharmacology 2004; 24: 141–149
   PubMed Web of Science ®Google Scholar
• Liebowitz M R, Gelenberg A J, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry 2005; 62: 190–198
   PubMed Web of Science ®Google Scholar
• Otto M W, Tuby K S, Gould R A, et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry 2001; 158: 1989–1992
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K, Weiss S, et al. Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Archives of General Psychiatry 1993; 50: 51–60
   PubMed Web of Science ®Google Scholar
• Cowley D S, Ha E H, Roy-Byrne P P. Determinants of pharmacologic treatment failure in panic disorder. Journal of Clinical Psychiatry 1997; 58: 555–561
   PubMed Web of Science ®Google Scholar
• Bruce S E, Vasile R G, Goisman R M, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. American Journal of Psychiatry 2003; 160: 1432–1438
   PubMed Web of Science ®Google Scholar
• Bandelow B, Behnke K, Lenoir S, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. Journal of Clinical Psychiatry 2004; 65: 405–413
   PubMed Web of Science ®Google Scholar
• Ball S G, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Journal of Clinical Psychiatry 2005; 66: 94–99
   PubMed Web of Science ®Google Scholar
• Sheehan D V, Burnham D B, Iyengar M K, et al. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Journal of Clinical Psychiatry 2005; 66: 34–40
   PubMed Web of Science ®Google Scholar
• Lepola U, Bergtholdt B, Lambert J S, et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry 2004; 65: 222– 229
   PubMed Web of Science ®Google Scholar
• Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 2004; 24: 118–125
   PubMed Web of Science ®Google Scholar
• Westenberg H G.M, Stein D J, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology 2004; 24: 49–55
   PubMed Web of Science ®Google Scholar
• Worthington J W, Pollack M H, Otto M W, et al. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacology Bulletin 1998; 34: 199–205
   PubMedGoogle Scholar
• Andersch S, Hetta J. A 15-year follow-up study of patients with panic disorder. European Psychiatry 2003; 18: 401–408
   PubMed Web of Science ®Google Scholar
• Stein D J, Versiani M, Hair T, et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Archives of General Psychiatry 2002; 59: 1111–1118
   PubMed Web of Science ®Google Scholar
• Stocchi F, Nordera G, Jokinen R H, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Journal of Clinical Psychiatry 2003; 64: 250–258
   PubMed Web of Science ®Google Scholar
• Ballenger J C. Remission rates in patients with anxiety disorders treated with paroxetine. Journal of Clinical Psychiatry 2004; 65: 1696–1707
   PubMed Web of Science ®Google Scholar
• Mavissakalian M R, Perel J M. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. Journal of Clinical Psychopharmacology 2002; 22: 294–299
   PubMed Web of Science ®Google Scholar
• Barlow D H, Gorman J M, Shear M K, et al. Cognitive–behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283: 2529–2536
   PubMed Web of Science ®Google Scholar
• Starcevic V, Linden M, Uhlenhuth E H, et al. Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: factors influencing psychiatrists’ treatment choices. Psychiatry Research 2004; 125: 41–52
   PubMed Web of Science ®Google Scholar
• Biondi M, Picardi A. Increased probability of remaining in remission from panic disorder with agoraphobia after drug treatment in patients who received concurrent cognitive– behavioural therapy: a follow-up study. Psychotherapy and Psychosomatics 2003; 72: 34–42
   PubMed Web of Science ®Google Scholar
• Simpson H B, Liebowitz M R, Foa E B, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive–compulsive disorder. Depression and Anxiety 2004; 19: 225–233
   PubMed Web of Science ®Google Scholar
• Starcevic V. Anxiety Disorders in Adults: A Clinical Guide. Oxford University Press, New York 2005
   Google Scholar